MX382840B - Regiones de anticuerpo modificado y sus usos. - Google Patents
Regiones de anticuerpo modificado y sus usos.Info
- Publication number
- MX382840B MX382840B MX2018001914A MX2018001914A MX382840B MX 382840 B MX382840 B MX 382840B MX 2018001914 A MX2018001914 A MX 2018001914A MX 2018001914 A MX2018001914 A MX 2018001914A MX 382840 B MX382840 B MX 382840B
- Authority
- MX
- Mexico
- Prior art keywords
- modified antibody
- antibody regions
- regions
- modified
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639729P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038538 WO2013163630A1 (en) | 2012-04-27 | 2013-04-26 | Modified antibody regions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX382840B true MX382840B (es) | 2025-03-13 |
Family
ID=49483948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001914A MX382840B (es) | 2012-04-27 | 2013-04-26 | Regiones de anticuerpo modificado y sus usos. |
| MX2014012978A MX360368B (es) | 2012-04-27 | 2013-04-26 | Regiones de anticuerpo modificado y sus usos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014012978A MX360368B (es) | 2012-04-27 | 2013-04-26 | Regiones de anticuerpo modificado y sus usos. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150065690A1 (enExample) |
| EP (2) | EP2841458A4 (enExample) |
| JP (1) | JP6470170B2 (enExample) |
| KR (2) | KR20150008082A (enExample) |
| CN (1) | CN104428317B (enExample) |
| AU (3) | AU2013251309B2 (enExample) |
| BR (1) | BR112014026740B1 (enExample) |
| CA (1) | CA2871807C (enExample) |
| HK (1) | HK1207654A1 (enExample) |
| IN (1) | IN2014DN08721A (enExample) |
| MX (2) | MX382840B (enExample) |
| RU (1) | RU2014147741A (enExample) |
| WO (1) | WO2013163630A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015259465A1 (en) * | 2014-05-13 | 2016-11-17 | Bioatla Llc | Conditionally active biological proteins |
| FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| IL260021B (en) | 2015-12-14 | 2022-09-01 | Macrogenics Inc | Bispecific molecules that are immunoreactive for pd1 and ctla4 and methods for using them |
| PT3430039T (pt) * | 2016-03-14 | 2026-01-16 | Univ Oslo | Imunoglobulinas manipuladas com ligação a fcrn alterada |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| WO2018160993A1 (en) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Compositions and methods for immunotherapy |
| WO2018161017A1 (en) | 2017-03-03 | 2018-09-07 | Obsidian Therapeutics, Inc. | Cd19 compositions and methods for immunotherapy |
| EP3806888B1 (en) | 2018-06-12 | 2024-01-31 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| JP7445995B2 (ja) * | 2018-10-31 | 2024-03-08 | バイオアトラ インコーポレイテッド | 抗ｃｔｌａ４抗体、抗体断片、それらの免疫コンジュゲートおよびそれらの使用 |
| CN113544153B (zh) * | 2019-01-03 | 2024-12-10 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| CN113966397A (zh) | 2019-03-08 | 2022-01-21 | 黑曜石疗法公司 | 人碳酸酐酶2组合物和用于可调调节的方法 |
| EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| WO2021030303A1 (en) | 2019-08-12 | 2021-02-18 | Voyager Therapeutics, Inc. | High-sensitivity immunoassay for the detection of frataxin in biofluids |
| WO2021040736A1 (en) | 2019-08-30 | 2021-03-04 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| US20220348937A1 (en) | 2019-09-06 | 2022-11-03 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| EP4225787A4 (en) * | 2020-05-21 | 2024-10-23 | Zydus Lifesciences Limited | FC VARIANT AND PRODUCTION THEREOF |
| KR20230015365A (ko) | 2020-05-22 | 2023-01-31 | 포르미콘 아게 | Ace2 융합 단백질 및 이의 용도 |
| US20240018499A1 (en) | 2020-10-29 | 2024-01-18 | Formycon Ag | ACE2 Fusion Proteins and Uses Thereof |
| MX2023009921A (es) | 2021-03-03 | 2023-09-05 | Formycon Ag | Formulaciones de proteinas de fusion ace2-fc. |
| WO2023094507A1 (en) | 2021-11-24 | 2023-06-01 | Formycon Ag | Improved ace2 fusion proteins |
| WO2023094571A1 (en) | 2021-11-25 | 2023-06-01 | Formycon Ag | Stabilization of ace2 fusion proteins |
| EP4386084A1 (en) | 2022-12-14 | 2024-06-19 | Formycon AG | Improved ace2 fusion proteins |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7361740B2 (en) * | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| AU2003286467B2 (en) * | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US7217798B2 (en) | 2003-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of Fc-fusion protein serum half-lives by mutagenesis |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2004041854A2 (en) | 2002-11-05 | 2004-05-21 | Affinium Pharmaceuticals, Inc. | Essential novel bacterial polypeptides |
| ES2897506T3 (es) * | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
| US7960512B2 (en) * | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20090010920A1 (en) * | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| JP2008504002A (ja) * | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法 |
| CN101189028B (zh) * | 2004-07-12 | 2013-05-29 | 马克罗基因公司 | 具有变异Fc区的抗体的鉴定和工程化以及使用方法 |
| KR100863776B1 (ko) * | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 |
| US7632497B2 (en) | 2004-11-10 | 2009-12-15 | Macrogenics, Inc. | Engineering Fc Antibody regions to confer effector function |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| CA2587617C (en) | 2004-11-12 | 2011-02-01 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| WO2006104989A2 (en) * | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| JP5105485B2 (ja) * | 2005-08-10 | 2012-12-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を有する抗体の同定および工学的改変およびその使用方法 |
| EP1943332A4 (en) * | 2005-10-14 | 2011-04-13 | Medimmune Inc | CELLULAR DISPLAY OF ANTIBODY LIBRARIES |
| CA3086659A1 (en) * | 2007-12-26 | 2009-07-09 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| ES2675730T3 (es) | 2008-06-04 | 2018-07-12 | Macrogenics, Inc. | Anticuerpos con unión alterada a FcRn y métodos de uso de los mismos |
| AU2010206681A1 (en) | 2009-01-23 | 2011-09-01 | Biogen Idec Ma Inc. | Stabilized Fc polypeptides with reduced effector function and methods of use |
| AU2010265933B2 (en) | 2009-06-26 | 2015-05-14 | Regeneron Pharmaceuticals, Inc. | Readily isolated bispecific antibodies with native immunoglobulin format |
| TWI667257B (zh) * | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| JP2013537415A (ja) * | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| US8483058B2 (en) | 2010-08-17 | 2013-07-09 | Qualcomm Incorporated | Systems and methods for traffic policing |
| BR112014000524B1 (pt) | 2011-07-15 | 2020-06-23 | Basell Poliolefine Italia S.R.L. | Cinta de poliolefina compreendendo um copolímero aleatório de propileno com 1-hexeno |
| CN113061993A (zh) * | 2011-09-30 | 2021-07-02 | 中外制药株式会社 | 离子浓度依赖性结合分子文库 |
| HK1203561A1 (en) * | 2012-01-19 | 2015-10-30 | 医用蛋白国际有限责任公司 | Stabilization of the anti-cd20 antibody rituximab |
-
2013
- 2013-04-26 WO PCT/US2013/038538 patent/WO2013163630A1/en not_active Ceased
- 2013-04-26 JP JP2015509206A patent/JP6470170B2/ja active Active
- 2013-04-26 EP EP13781110.5A patent/EP2841458A4/en not_active Withdrawn
- 2013-04-26 CA CA2871807A patent/CA2871807C/en active Active
- 2013-04-26 IN IN8721DEN2014 patent/IN2014DN08721A/en unknown
- 2013-04-26 EP EP18209149.6A patent/EP3470433B1/en active Active
- 2013-04-26 RU RU2014147741A patent/RU2014147741A/ru unknown
- 2013-04-26 MX MX2018001914A patent/MX382840B/es unknown
- 2013-04-26 CN CN201380022401.0A patent/CN104428317B/zh active Active
- 2013-04-26 MX MX2014012978A patent/MX360368B/es active IP Right Grant
- 2013-04-26 KR KR1020147030719A patent/KR20150008082A/ko not_active Ceased
- 2013-04-26 US US14/396,851 patent/US20150065690A1/en not_active Abandoned
- 2013-04-26 KR KR1020207009090A patent/KR20200037434A/ko not_active Ceased
- 2013-04-26 AU AU2013251309A patent/AU2013251309B2/en active Active
- 2013-04-26 HK HK15108290.3A patent/HK1207654A1/xx unknown
- 2013-04-26 BR BR112014026740-5A patent/BR112014026740B1/pt active IP Right Grant
-
2017
- 2017-09-08 AU AU2017225111A patent/AU2017225111B2/en active Active
-
2018
- 2018-03-02 US US15/910,588 patent/US10954288B2/en active Active
-
2019
- 2019-04-01 AU AU2019202229A patent/AU2019202229B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX360368B (es) | 2018-10-29 |
| AU2019202229A1 (en) | 2019-04-18 |
| JP6470170B2 (ja) | 2019-02-13 |
| EP3470433C0 (en) | 2025-12-03 |
| EP3470433A1 (en) | 2019-04-17 |
| IN2014DN08721A (enExample) | 2015-05-22 |
| BR112014026740A2 (pt) | 2017-06-27 |
| US20150065690A1 (en) | 2015-03-05 |
| AU2013251309A1 (en) | 2014-10-30 |
| CA2871807A1 (en) | 2013-10-31 |
| AU2019202229B2 (en) | 2021-02-11 |
| CA2871807C (en) | 2022-10-04 |
| MX2014012978A (es) | 2015-02-05 |
| RU2014147741A (ru) | 2016-06-20 |
| EP3470433B1 (en) | 2025-12-03 |
| KR20150008082A (ko) | 2015-01-21 |
| HK1207654A1 (en) | 2016-02-05 |
| CN104428317B (zh) | 2018-08-28 |
| US20180186863A1 (en) | 2018-07-05 |
| WO2013163630A1 (en) | 2013-10-31 |
| JP2015515497A (ja) | 2015-05-28 |
| EP2841458A1 (en) | 2015-03-04 |
| BR112014026740B1 (pt) | 2022-10-04 |
| AU2013251309B2 (en) | 2017-06-22 |
| BR112014026740A8 (pt) | 2021-06-15 |
| US10954288B2 (en) | 2021-03-23 |
| KR20200037434A (ko) | 2020-04-08 |
| EP2841458A4 (en) | 2015-09-16 |
| AU2017225111A1 (en) | 2017-09-28 |
| AU2017225111B2 (en) | 2019-01-03 |
| CN104428317A (zh) | 2015-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX382840B (es) | Regiones de anticuerpo modificado y sus usos. | |
| CR20150329A (es) | Inmunoglobulinas heterodiméricas | |
| ECSP12012105A (es) | Antídotos de Anticoagulantes | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| CL2014002954A1 (es) | Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos. | |
| UY34876A (es) | Anticuerpos anti-egfr y usos de los mismos | |
| CL2014002616A1 (es) | Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos. | |
| CL2014001984A1 (es) | Anticuerpos humanizados que reconozen alfa-sinucleína; metodo de produccion y sus usos. | |
| UY34721A (es) | Anticuerpos anti-hla-b*27 y usos de éstos. | |
| NI201400061A (es) | Anticuerpos anti - phf - tau y sus usos | |
| CL2015001507A1 (es) | Proteínas de unión al antígeno bcma | |
| UY34680A (es) | Anticuerpos humanos anti-cd27, métodos, y usos | |
| IL233934B (en) | Cd47 antibodies, compositions comprising the same and uses thereof | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| UY34587A (es) | Formulaciones estabilizadas que contienen anticuerpos antiang2 | |
| UY34484A (es) | Benzotienilo-pirrolotriazinas disustituidas y sus usos | |
| UY34652A (es) | Anticuerpos humanos frente a toxinas de clostridium difficile | |
| CR20150247A (es) | Anticuerpos de antihemaglutinina y métodos de uso | |
| EA201590173A1 (ru) | Иммуноконъюгаты, содержащие антитела к cd22 | |
| EA201491357A1 (ru) | Анти-lrp5 антитела и способы их применения | |
| CL2014001640A1 (es) | Composiciones y metodos para anticuerpos dirigidos factor de p; y usos del anticuerpo. | |
| CL2014002204A1 (es) | Formulacion de anticuerpo anti il-17 y sus usos. | |
| ECSP13012997A (es) | Antídotos anticoagulantes | |
| CR20140124A (es) | Metabolitos de transclomifeno y usos de los mismos | |
| ECSP13012481A (es) | Composiciones de anticuerpo anti-vegfr-3 |